^
Association details:
| Biomarker: | IL13 elevation |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | bortezomib (Proteasome inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Pretreatment Serum Levels of IL-1 Receptor Antagonist and IL-4 Are Predictors of Overall Survival in Multiple Myeloma Patients Treated with Bortezomib
Published date:
12/26/2021
Excerpt:
We observed that a higher serum pretreatment level of IL-13 is an independent predictor of longer PFS in MM patients treated with bortezomib-based chemotherapy...Only IL-13 pretreatment serum level was found to significantly impact PFS in newly diagnosed MM patients treated with bortezomib-based regimens.
DOI:
10.3390/jcm11010112